Håkan Björklund
Håkan Björklund
Chairman

Born 1956

Board member since 2016

Member of the Nomination committee and Compensation & Benefits committee

Education:  Ph.D. from Karolinska Institutet in Stockholm.

Other current appointments: Currently serves as Industry Executive at Avista Capital Partners.

Previous appointments: Extensive international background in the life science industry, from both R&D and sales and marketing. Håkan has served as a Member of the Board of Directors of several international life science companies including Alere, Coloplast, Danisco, and Lundbeck. Between 2001 and 2007, Håkan Björklund also served as member of the Board of Directors for Biovitrum.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Shareholding in the company: 15,800

 

David Allsop
David Allsop

Born 1963

Board member since 2018

Member of the Compensation & Benefits committee

Education: BSc Hons Chemistry from Coventry University, UK.

Other appointments: Director and sole employee in U-R-NOT Ltd., through which Mr Allsop offers advisory services to the pharma industry.

Previous appointments: More than 30 years’ of experience from research as well as marketing within the pharmaceuticals and health care industries. International experience from the pharmaceutical and biotechnology industry and a commercial and general management background. Until January 2018, Head of International in Amicus Therapeutics Ltd. A number of senior positions in Biogen 1998–2015.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Shareholding in the company: 0

Annette Clancy
Annette Clancy

Born 1954

Board member since 2014

Member of the Scientific committee

 

Education:  BSc Hons Pharmacology from Bath University UK.

Other appointments: Non-executive Chairman of the Board, Enyo SA and Lysogene SA. Member of the Board of Directors, Obseva SA.

Previous appointments: Senior Advisor, Biopharmaceutical Team of Frazier Healthcare.  Chair of the Board of Directors, Genable Therapeutics. Non-Executive Board Director, Silence Therapeutics plc. and Clavis Pharma. Head of Transaction and Alliance Management at GlaxoSmithKline (GSK).

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Shareholding in the company: 3,414

Matthew Gantz
Matthew Gantz

Born 1965

Board member since 2012

Member of the Compensation & Benefits committee

 

Education: BA Princeton University and MBA from Harvard Business School.

Other appointments: CEO of OxThera AB. Member of the board for Pennsylvania Life Sciences Association and Marine Corps Scholarship Foundation.

Previous appointments: Executive Vice President of BTG Plc, Founder and previously CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc., VP Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Shareholding in the company: 0

Lennart Johansson
Lennart Johansson

Born 1955

Board member since 2010

Member of the Audit committee

 

Education: MBA from Stockholm School of Economics.

Other appointments: Member of the management team and Senior Advisor at Patricia Industries (division of Investor AB). Chairman of the board of Fastighets AB Tingshuset 13, board member of Vectura Fastigheter AB, HI3G, Chalmers Ventures and Bonesupport AB.

Previous appointments: Chairman of the Board of Vectura Fastigheter AB, CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB and Gambro Holding AB.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: No

Shareholding in the company: 20,000

Helena Saxon
Helena Saxon

Born 1970

Board member since 2011

Member of the Audit committee and the Compensation & Benefit committee

 

Education: MSc from Stockholm School of Economics.

Other appointments: CFO at Investor AB. Board member of SEB

Previous appointments: CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: No

Shareholding in the company: 15,500

Hans GCP Schikan
Hans GCP Schikan

Born 1958

Board member since 2011

Member of the Audit committee and the Scientific committee

 

Education:  Pharmacist, Utrecht University.

Other appointments: Chairman of the Board of Directors of Interna, The Netherlands and Complix, Belgium. Member of the Board of Directors of Vicore Pharma, Sweden, Therachon, Switzerland as well as of the Dutch Top Sector Life Sciences & Health, The Netherlands. Advisor to various organisations in Life Sciences & Health.

Previous appointments: CEO of Prosensa, Director of the Supervisory Board of Prosensa, Member of the Board of Directors of Hansa Medical, Wilson Therapeutics and Asceneuron. Various senior management positions within former Organon and Genzyme.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Shareholding in the company: 4,000

 

 

Elisabeth Svanberg
Elisabeth Svanberg

Born 1961

Board member since 2018

Member of the Scientific committee

 

Education: MD and PhD from the University of Gothenburg, Sweden, Associate Professor of surgery.

Other appointments: Currently serves as Chief Development Officer at Ixaltis SA in France since 2016. Member of the Board of Directors of PledPharma AB.

Previous appointments: Board member of Follicum AB and of the Swedish American Chamber of Commerce New York. Head of the Established Products Group at Janssen Pharmaceuticals 2014–2016. Lead the development of a novel diabetes medicine and served as Head of Medical Affairs for the Intercontinental region at Bristol Myers Squibb (BMS) in the US 2007–20014. Held leading roles in R&D for metabolic diseases at Serono International, Switzerland, 2000-2007.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Shareholding in the company: 260

Bo-Gunnar Rosenbrand
Bo-Gunnar Rosenbrand
Employee Representative

Born 1963

Board member since 2006

Deputy board member 2001 – 2005

Representative of the council for negotiation and cooperation

Education: Laboratory engineer.

Independent of the company and its executive management: No

Independent in relation to major shareholders of the Company: Yes

Shareholding in the company: 9,759

Pia Axelson
Pia Axelson
Employee Representative

Born 1962

Board member since 2017

Deputy board member since 2009

Representative of the council for negotiation and cooperation

 

Education: Laboratory engineer

Independent of the company and its executive management: No

Independent in relation to major shareholders of the Company: Yes

Shareholding in the company:  6,935

Emily Chamberlain
Deputy for the Employee Representatives

Born 1990. MSc Biochemistry. Scientist. Deputy board member since December 2018. Deputy representative of the council for negotiation and cooperation.

Kristin Strandberg
Deputy for the Employee Representatives

Born: 1989. MSc Biotechnology. Scientist. Deputy board member since December 2018. Deputy representative of the council for negotiation and cooperation.

Björn Ohlsson
Auditor

Authorised Public Accountant, Ernst & Young AB.